Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a report issued on Wednesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, Maxim Group reissued a “hold” rating on shares of Galmed Pharmaceuticals in a research report on Friday, April 4th.

Galmed Pharmaceuticals Stock Performance

Galmed Pharmaceuticals stock opened at $1.25 on Wednesday. Galmed Pharmaceuticals has a fifty-two week low of $1.15 and a fifty-two week high of $23.80. The firm’s 50-day simple moving average is $1.59 and its 200 day simple moving average is $2.46. The stock has a market cap of $2.07 million, a PE ratio of -0.08 and a beta of 0.49.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC bought a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned approximately 3.97% of Galmed Pharmaceuticals at the end of the most recent reporting period. 76.14% of the stock is currently owned by hedge funds and other institutional investors.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.